PharmaShots | Incisive News in 3 Shots

Subscribe Now

P-III Study

Kashiv BioSciences Reports the First Patient Enrolment of ADL018 (biosimilar, omalizumab) in the P-III Clinical Study for Chronic Spontaneous Urticaria

Kashiv BioSciences Reports the First Patient Enrolment of ADL018 (biosimilar, omalizumab) in the P-III Clinical Study for Chronic...

October 3, 2023

Amneal Reports P-III Study Results of IPX203 for the Treatment of Parkinson’s Disease

Amneal Reports P-III Study Results of IPX203 for the Treatment of Parkinson’s Disease

August 25, 2023

Shanghai Biomabs Pharmaceutical Reports P-III Study Results of CMAB008 (biosimilar, infliximab) for Rheumatoid Arthritis

Shanghai Biomabs Pharmaceutical Reports P-III Study Results of CMAB008 (biosimilar, infliximab) for Rheumatoid Arthritis

August 14, 2023

STADA and Xbrane Report P-III Study Results of Ximluci (biosimilar, ranibizumab) for the Treatment of Neovascular Age-Related Macular Degeneration

STADA and Xbrane Report P-III Study Results of Ximluci (biosimilar, ranibizumab) for the Treatment of Neovascular Age-Related Macu...

June 23, 2023

Samsung Bioepis Presents 52 Weeks P-III Study Results of SB15, Proposed biosimilar to Eylea (aflibercept) for Neovascular Age-Related Macular Degeneration at ARVO 2023

Samsung Bioepis Presents 52 Weeks P-III Study Results of SB15, Proposed biosimilar to Eylea (aflibercept) for Neovascular Age-Rela...

April 25, 2023

Dong-A ST Reports P-III Study Results of Ustekinumab Biosimilar DMB-3115 for the Treatment of Chronic Plaque Psoriasis

Dong-A ST Reports P-III Study Results of Ustekinumab Biosimilar DMB-3115 for the Treatment of Chronic Plaque Psoriasis

January 17, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us